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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERCoffee Drinking and Heart Health 1043James H. O’Keefe, Salman K. Bhatti, Harshal R. Patil, James J. DiNicolantonio, Sean C. Lucan,
Carl J. Lavie
Coffee is the most widely consumed beverage in the United States after water. Coffee is a
complex beverage containing hundreds of biologically active compounds. O’Keefe and
colleagues review data on the cardiovascular (CV) effects of coffee and conclude that habitual
consumption may reduce the risk of developing diabetes, hypertension, obesity, and
depression. A growing body of data suggests that habitual coffee consumption is neutral to
beneﬁcial regarding the risks for a variety of adverse CV outcomes. Moreover, large
epidemiological studies suggest that regular coffee drinkers have reduced risks for CV and
all-cause mortality.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYPercutaneous Mitral Valve Interventions in the ACCESS-EU Study 1052
Francesco Maisano, Olaf Franzen, Stephan Baldus, Ulrich Schäfer, Jörg Hausleiter,
Christian Butter, Gian Paolo Ussia, Horst Sievert, Gert Richardt, Julian D. Widder,
Tiziano Moccetti, Wolfgang Schillinger
The ACCESS-EU (ACCESS-Europe A Two-Phase Observational Study of the MitraClip
System in Europe) is a prospective, multicenter, nonrandomized registry designed to assess
the post-approval safety, efﬁcacy, and economic impacts of MitraClip therapy (Abbott
Vascular Inc., Santa Clara, California) for mitral regurgitation (MR). A total of 567 patients
with signiﬁcant MR underwent MitraClip therapy at 14 European sites. Mean logistic
EuroSCORE at baseline was 23; 84.9% of patients were in New York Heart Association
functional class III or IV, and 52.7% patients had an ejection fraction 40%. The MitraClip
implant rate was 99.6%. The 30-day mortality was 3.4%, and 1-year survival was 81.8%. A
total of 6.3% required mitral valve surgery within 12 months. These results show that most
patients undergoing MitraClip therapy are high-risk elderly patients, with functional MR; for
these patients, the MitraClip procedure appears to be effective, with low rates of hospital
mortality and adverse events.
Editorial Comment: Saibal Kar, p. 1062(continued on page A-26)
SEPTEMBER 17, 2013 (continued) A-26HEART FAILUREQili Qiangxin in Chronic Heart Failure 1065Xinli Li, Jian Zhang, Jun Huang, Aiqun Ma, Jiefu Yang, Weimin Li, Zonggui Wu, Chen Yao,
Yuhui Zhang, Wenming Yao, Boli Zhang, Runlin Gao, for the Efﬁcacy and Safety of Qili Qiangxin
Capsules for Chronic Heart Failure Study Group
Qili Qiangxin capsules are a traditional Chinese medicine derived from 11 different herbs
that has been approved for the treatment of chronic heart failure (CHF) in China. Li and
colleagues performed a randomized, placebo-controlled trial of over 500 CHF patients on
standard CHF therapy. Subjects randomized to Qili Qiangxin demonstrated a signiﬁcantly
greater reduction than the placebo group in N-terminal pro–B-type natriuretic peptide, with
48.5% of patients in the Qili Qiangxin capsule group having at least a 30% reduction
compared with 32.8% of patients in the placebo group after 12 weeks. There were also better
effects with Qili Qiangxin capsules on New York Heart Association functional classiﬁcation,
left ventricular ejection fraction, 6-min walking distance, and quality of life. These results
conﬁrm that there is at least a short-term beneﬁt of adding Qili Qiangxin to standard CHF
therapy.
Editorial Comment: W. H. Wilson Tang, Yanming Huang, p. 1073HEART RHYTHM DISORDERSSudden Syncope With Normal Heart and ECG 1075
Jean-Claude Deharo, Regis Guieu, Alexis Mechulan, Eric Peyrouse, Nathalie Kipson, Jean Ruf,
Victoria Gerolami, Gianluigi Devoto, Vanna Marrè, Michele Brignole
Deharo and colleagues investigated the clinical and laboratory ﬁndings of patients affected by
sudden-onset syncope without prodrome who had a normal heart and normal electrocardiogram.
Patients presenting with this condition were compared with a control group of patients with
symptoms typical of vasovagal syncope (VVS). The study group patients were older, had
experienced fewer episodes of syncope, and had a more recent onset of symptoms. The study
group had lower median baseline plasma adenosine values than the VVS group, with a value
of 0.36 discriminating between groups with 73% sensitivity and 93% speciﬁcity. Tilt table
testing was more frequently positive in the VVS group than in the study group (74% vs.
33%), but both groups had similar rates of prolonged pauses after adenosine or adenosine
triphosphate infusion. The authors propose that these patients with low adenosine levels may
have idiopathic atrioventricular block as the etiology for their syncope.(continued on page A-27)
SEPTEMBER 17, 2013 (continued) A-27CARDIAC IMAGINGPredictive Value of Carotid Plaque Hemorrhage 1081Tobias Saam, Holger Hetterich, Verena Hoffmann, Chun Yuan, Martin Dichgans, Holger Poppert,
Thomas Koeppel, Ulrich Hoffmann, Maximilian F. Reiser, Fabian Bamberg
Saam and colleagues conducted a systematic review and meta-analysis to determine precise
estimates of the predictive value of carotid intraplaque hemorrhage (IPH) as determined by
magnetic resonance imaging (MRI) for predicting cerebrovascular events. Eight eligible
studies including 689 participants who underwent carotid MRI were included. The
prevalence of IPH at baseline was high (49%). The presence of IPH was associated with a
w6-fold higher risk for events, with an annualized event rate in subjects with IPH of 18%
compared with 2.4% in patients without IPH. These results conﬁrm that MRI-detected IPH
is a strong marker of subsequent cerebrovascular risk, but more work is needed to standardize
imaging and classiﬁcation protocols.PULMONARY DISORDERSPulmonary Denervation for Pulmonary Hypertension 1092Shao-Liang Chen, Feng-Fu Zhang, Jing Xu, Du-Jiang Xie, Ling Zhou, Thach Nguyen, Gregg W. Stone
Chen and colleagues previously demonstrated that pulmonary artery (PA) denervation (DN)
abolished experimentally elevated PA pressure in an animal model. This study tested the
safety and efﬁcacy of PADN for patients with idiopathic pulmonary artery hypertension
(IPAH) not responding optimally to medical therapy. PADN was performed at the
bifurcation of the main PA and at the ostial right and left PAs using a proprietary device.
Serial echocardiography, right heart catheterization, and a 6-min walk test (6MWT) were
performed and compared with the results in a control group who declined to undergo
PADN. Subjects who underwent the PADN procedure showed signiﬁcant reduction of
mean PA pressure (from 55 to 36 mm Hg) and an approximately 150-m improvement in the
6MWT at 3 months. This small study supports the concept of PADN for IPAH and
suggests the need for a randomized study of this therapy.
Editorial Comment: Nazzareno Galiè, Alessandra Manes, p. 1101(continued on page A-28)
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Janne Mykland Hilde, Ingunn Skjørten, Ole Jørgen Grøtta, Viggo Hansteen, Morten Nissen Melsom,
Jonny Hisdal, Sjur Humerfelt, Kjetil Steine
Hilde and colleagues studied right ventricular (RV) function and structure in patients with
chronic obstructive pulmonary disease (COPD). All COPD patients underwent right heart
catheterization to exclude elevated left atrial pressure as a cause of pulmonary hypertension
(PH), which was deﬁned as mean pulmonary artery pressure >25 mm Hg. RV wall thickness
and RV dimension were increased in COPD patients compared to healthy controls, particularly
those with PH. Similarly, RV isovolumic acceleration, performance index, and strain
deteriorated signiﬁcantly with COPD, especially for those with PH. These results show
impaired RV systolic function along with RV hypertrophy and dilation in patients with
COPD.
Editorial Comment: Lewis J. Rubin, p. 1112VASCULAR DISEASEVascular Health in Kawasaki Disease 1114
Elif Seda Selamet Tierney, Dana Gal, Kimberly Gauvreau, Annette L. Baker, Shari Trevey,
Stephen R. O’Neill, Michael R. Jaff, Sarah de Ferranti, David R. Fulton, Steven D. Colan,
Jane W. Newburger
Selamet Tierney and colleagues studied patients with previous Kawasaki disease (KD) who
never developed coronary artery aneurysms (CAs) to assess their vascular health. A total of
203 subjects, age 11 to 29 years, with KD onset >12 months earlier, who had either no CAs
or minimal CAs during their initial illness underwent a battery of tests including measuring
endothelial function (Endothelial Pulse Amplitude Testing [Endo-PAT] index), intima-
media thickness (IMT), fasting lipid proﬁle, and C-reactive protein. Compared with
controls, KD patients had a higher peak velocity in the left common carotid artery and higher
pulsatility index of both carotids; however, there were no differences in the Endo-PAT index,
carotid IMT, or stiffness. These results suggest that in children and young adults with
previous KD whose maximum CA dimensions were either always normal or mildly ectatic
may not be at increased vascular risk in the future.
Editorial Comment: Jane C. Burns, Lori B. Daniels, p. 1122
